- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02281604
In-line Filters on ICU
February 28, 2019 updated by: Professor Kai Zacharowski, M.D., Ph.D., FRCA, Johann Wolfgang Goethe University Hospital
The purpose of this study is to determine whether the use of 0.2/1.2
microliter in-line filter reduces the incidence of severe vasoplegia comparing to the 5 microliter filter.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
3281
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All patients, which will be treated on the anaesthesiological/surgical ICU of the University Hospital Frankfurt between 2013 - 2014
Description
Inclusion Criteria:
- all patients
Exclusion Criteria:
- Younger than 18 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
0.2/1.2 microliter filter
Use of 0.2/1.2
microliter filters for intravenous drug administration
|
|
5 mircroliter filter
Use of 5 microliter filters for intravenous drug administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of severe vasoplegia
Time Frame: participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
|
participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Organ dysfunction
Time Frame: participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
|
Severity of organdysfunction (SOFA-Score), incidence and severity of respiratory failure (Horovitz- Index), incidence and severity of acute kidney failure (RIFLE criteria), incidence and severity of delirium
|
participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
|
|
Inflammation
Time Frame: participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
|
Interleukin-6
|
participants will be followed for the duration of intensive care unit stay, an expected average of 1 week
|
|
Duration of ICU and hospital stay
Time Frame: participants will be followed for the duration of intensive care unit/ hospital stay, an expected average of 1 or 4 week (s), respectively
|
participants will be followed for the duration of intensive care unit/ hospital stay, an expected average of 1 or 4 week (s), respectively
|
|
|
In-hospital mortality
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 4 weeks
|
|
|
Morbidity
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 4 weeks
|
Incidence of preoperative myocardial infarction, stroke, pneumonia, sepsis and acute kidney failure according to routine documentation
|
participants will be followed for the duration of hospital stay, an expected average of 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kai Zacharowski, M.D., University Hospital Frankfurt. Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
January 1, 2016
Study Completion (Actual)
December 1, 2018
Study Registration Dates
First Submitted
October 29, 2014
First Submitted That Met QC Criteria
October 30, 2014
First Posted (Estimate)
November 2, 2014
Study Record Updates
Last Update Posted (Actual)
March 1, 2019
Last Update Submitted That Met QC Criteria
February 28, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- In-line Filter 13/14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Micropore Filters
-
Northwestern UniversityCompleted
-
University of MichiganBard LtdTerminatedVena Cava FiltersUnited States
-
Group of Research in Minimally Invasive TechniquesSERVEI (Sociedad Española de Radiología Vascular e Intervencionista)Completed